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Introduction
Clinical studies have demonstrated that adoptive transfer
of allogeneic Natural Killer (NK) cells can play a thera-
peutic role in hematological malignancies and potentially
solid tumors. We established and characterized ex vivo
methods to obtain murine NK1.1+ cells from mouse fetal
liver. These cells represent an orthologous cell type for
expanded cells from human cord or placenta. Persistence,
engraftment, expansion and anti-tumor efficacy of these
fetal liver derived intermediate NK(FLiNK) cells were
evaluated in allogeneic or syngeneic recipient mice after
adoptive transfer. This study supports the possibility of
clinical therapeutic application of ex vivo generated NK
cells from HSC sources.
Material and Methods
HSC were isolated from C57BL/6(B6) fetuses (day 18-20
of gestation) using a Hematopoietic Stem Cell isolation kit
and cultured with a cytokine cocktail in three stages over
21 days. FLiNK cells were harvested and characterized
prior to administration. MC38-luciferase+ cells (2X105) or
Renca-luciferase+ cells were injected into recipient mice
via tail vein to establish pulmonary metastasis. Tumor
bearing mice received 2.5Gy irradiation followed by
5-10X106 NK cells by tail vein injection and administra-
tion of rIL-2 (200,000IU/mouse, intra-peritoneal injection
twice/day for 5days). Tumor growth was measured by
IVIS, lung weight, total body weight obtained, and tumor
number recorded.
Results
c-kit+CD16-NK1.1-CD34- NK progenitor cells were suc-
cessfully isolated from mouse fetal livers, and propa-
gated over 21 days to give rise to FLiNK cells, which are
CD3-NK1.1+NKp46+CD94+NKG2D+KLRG1+CD244+.
Adoptive transfer of syngeneic FLiNK cell significantly
inhibits development of mouse lung metastasis, while
allogenic FLiNK showed slightly inhibitory effects. Com-
pared with conventional splenic NK cells, FLiNK cells
exhibited higher in vitro cytolytic activity against MC38
(FLiNK 30.2±4.0 vs splenic NK 22.4±0.5, P6 B6 FLiNK
cells inhibited syngeneic MC38 tumor growth in B6
mice. Survival times were significantly prolonged from
the 36 days in saline (no NK) group (n=17) to 50 days
in FLiNK recipients(n=15), (p < 0.05). Using allogeneic
Balb/c Renca tumor bearing mice, B6 FLiNK also
demonstrated anti-tumor effects, with control (no NK)
survival of 25 days(n=5) compared with 30 days in the
FLiNK group (n=5).
Conclusions
This study successfully established an ex vivo protocol to
obtain NK1.1+ cells from c-kit+CD16-NK1.1-CD34-NK
progenitor cells from the mouse fetal liver. These FLiNK
cells, on adoptive transfer, inhibit development of syn-
geneic and allogenic mouse lung metastasis. Proposed
clinical trials of allogeneic NK cells in patients with pul-
monary metastatic renal cancer are in preparation.
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